Twist Bioscience Co. (NASDAQ:TWST) Receives Consensus Rating of “Buy” from Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been given an average rating of “Buy” by the eight research firms that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $46.63.

TWST has been the topic of several recent research reports. Guggenheim initiated coverage on shares of Twist Bioscience in a research note on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price target on the stock. Barclays lifted their price target on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Robert W. Baird lifted their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Scotiabank lifted their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research note on Monday, May 6th. Finally, TD Cowen lifted their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, June 13th.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,132 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total value of $37,061.68. Following the completion of the sale, the chief executive officer now owns 514,149 shares in the company, valued at $16,833,238.26. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Twist Bioscience news, COO Patrick John Finn sold 2,174 shares of the stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total transaction of $65,480.88. Following the completion of the transaction, the chief operating officer now owns 176,206 shares in the company, valued at $5,307,324.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,132 shares of the stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $32.74, for a total transaction of $37,061.68. Following the transaction, the chief executive officer now owns 514,149 shares of the company’s stock, valued at approximately $16,833,238.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,163 shares of company stock worth $666,151. 3.92% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently modified their holdings of the company. Swiss National Bank lifted its position in Twist Bioscience by 1.5% during the third quarter. Swiss National Bank now owns 125,600 shares of the company’s stock valued at $2,545,000 after purchasing an additional 1,800 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Twist Bioscience by 3.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 442,504 shares of the company’s stock worth $8,965,000 after acquiring an additional 14,511 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Twist Bioscience by 4.8% in the third quarter. Deutsche Bank AG now owns 51,208 shares of the company’s stock worth $1,037,000 after buying an additional 2,368 shares during the period. Invesco Ltd. increased its stake in shares of Twist Bioscience by 1,496.2% in the third quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock worth $16,836,000 after buying an additional 778,944 shares during the period. Finally, Dark Forest Capital Management LP increased its stake in shares of Twist Bioscience by 121.3% in the third quarter. Dark Forest Capital Management LP now owns 29,451 shares of the company’s stock worth $597,000 after buying an additional 16,142 shares during the period.

Twist Bioscience Price Performance

TWST opened at $50.97 on Friday. Twist Bioscience has a one year low of $14.42 and a one year high of $55.26. The company’s 50 day simple moving average is $41.89 and its 200-day simple moving average is $37.52. The stock has a market capitalization of $2.97 billion, a P/E ratio of -15.17 and a beta of 1.78.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. During the same period last year, the firm earned ($1.06) earnings per share. The business’s revenue for the quarter was up 25.1% on a year-over-year basis. As a group, analysts anticipate that Twist Bioscience will post -3.08 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.